<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04878705</url>
  </required_header>
  <id_info>
    <org_study_id>TWP-201-11</org_study_id>
    <nct_id>NCT04878705</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of TWP-201 in Healthy Female Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Dose, Escalation, Phase I Clinical Trial to Evaluate the Safety and Tolerability of TWP-201 in Healthy Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong TheraWisdom Biopharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong TheraWisdom Biopharma Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled, single dose, escalation, phase&#xD;
      I clinical trial to evaluate the safety and tolerability of recombinant human follicle&#xD;
      stimulating hormone Fc fusion protein injection (TWP-201) in healthy female subjects. The&#xD;
      objective of the trial is to evaluate the safety and tolerability of TWP-201 in healthy&#xD;
      female subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events, serious adverse and abnormal laboratory values event (defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE V5.0)).</measure>
    <time_frame>An average of 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum measured plasma concentration (Cmax) of TWP-201;</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax) of TWP-201;</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2) of TWP-201.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics(PD).</measure>
    <time_frame>28 days</time_frame>
    <description>Determination of serum concentrations of FSH, E2 and LH after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics(PD).</measure>
    <time_frame>28 days</time_frame>
    <description>The number of follicles after dosing. The size of follicles after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity profile of TWP-201.</measure>
    <time_frame>28 days</time_frame>
    <description>Blood samples will be collected from subjects post treatment for assessment to detect the presence of anti-drug antibodies and neutralizing antibodies.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>TWP-201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TWP-201</intervention_name>
    <description>a single subcutaneous injection</description>
    <arm_group_label>TWP-201</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>a single subcutaneous injection</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body weight ≥ 45 kg, 19 ≤ body mass index (BMI) ≤ 28 kg /m2;&#xD;
&#xD;
          -  Women with sexual experience, potential fertility and regular menstrual cycle (25-34&#xD;
             days) (including boundary value);&#xD;
&#xD;
          -  The levels of sex hormones were normal or abnormal without clinical significance at&#xD;
             the time of screening;&#xD;
&#xD;
          -  The physiological structure of uterus and bilateral ovaries was normal or abnormal by&#xD;
             ultrasound examination, without clinical significance;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known the history of stage III / IV endometriosis, submucosal myoma and endocrine&#xD;
             abnormality within 6 months before enrollment;&#xD;
&#xD;
          -  Known the history of ovarian hyperstimulation syndrome (OHSS);&#xD;
&#xD;
          -  Premature ovarian failure, decreased ovarian reserve function (Antral Follicle&#xD;
             Counting &lt; 3), high ovarian response, polycystic ovary syndrome, unexplained vaginal&#xD;
             bleeding or endometrial hyperplasia;&#xD;
&#xD;
          -  Any FSH or HMG preparations were used within 3 months before the first study;&#xD;
&#xD;
          -  Pregnancy or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shengbin Ren</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shengbin Ren</last_name>
    <phone>8021-60167707</phone>
    <email>shengbin.ren@therawisdom.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Second University Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qin Yu</last_name>
      <phone>8028-85501952</phone>
      <email>908929936@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Lingli Zhang</last_name>
      <phone>8028-85501952</phone>
      <email>zhanglingli@scu.edu.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

